Summary:
Neko Health raised $260M, valuing it at $1.8B.
Waitlist has grown from 40k to 100k+ in a few months.
Customers pay about $373 for comprehensive body scans.
80% of customers have rebooked services after initial visits.
Competition includes Prenuvo and Ezra, with higher price points.
If WebMD hates to see you coming, you’re probably the target customer for Neko Health.
The Stockholm-based startup, co-founded in 2018 by Spotify founder and CEO Daniel Ek, just closed a $260 million Series B round, valuing the company at $1.8 billion. If that feels like a lot, you might be underestimating the demand — Neko’s waitlist has grown from 40k people just months ago to 100k+ today, according to TechCrunch.
For ~$373 a Pop...
Customers step into a monochromatic, futuristic clinic room:
- A cylindrical chamber filled with 70 sensors and dozens of cameras creates a composite picture of your body using 50 million data points.
- Patients then move to an exam bed for two more scans, including eye and blood-pressure measurements, a grip test, and a blood test.
Each hourlong visit includes a doctor consultation and recommendations for annual follow-ups if needed; according to TechCrunch, 80% of customers have rebooked and prepaid for another appointment. So far, Neko has scanned 10k patients at its clinics in Stockholm and London. With its freshly raised capital, the company is eyeing expansion into new markets, like the US.
Scanning the Competition
Neko isn’t the only startup looking to take your money in return for a hefty dose of health anxiety, though most of its competitors focus on MRI tech:
- Prenuvo charges $1,000 for a torso MRI and $2,500 for full-body imaging, recently surpassing 100k scans.
- Ezra’s offerings range from a $1,500 full-body “flash” MRI scan to a $2,700 full-body MRI and CT scan.
One of the Problems with the Practice...
… are those price tags. While celebrities and VCs might love full-body scans, your wallet might not. Plus, some physicians worry that full-body scans will do more harm than good, leading to false positives, extra costs, and unnecessary anxieties for patients. Luckily, at these prices, many of us don’t have to weigh the pros and cons quite yet.
Comments